Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Liver-directed AAV transgene expression is enhanced by ImmTOR nanoparticles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 ImmTOR admixed to AAV provides higher transduction and mRNA and protein expression but similar inhibition of IgG response. (A to D) Groups of C57BL/6 female mice (n = 20) were injected with AAV8-SEAP (5 × 1011 vg/kg) alone or combined with 100 μg of ImmTOR, administered either as an admix or sequentially (non-admix) as shown in experimental scheme (A). Livers were harvested from five mice per group at each time point and analyzed for vector DNA (B) and SEAP mRNA (C). Sera from the same animals were analyzed for SEAP activity (D). Vector genome copies (vg per cell) and SEAP mRNA fold increase [normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH)] over naïve mice. (E) C57BL/6 female mice (n = 10 per group) were injected with AAV8-SEAP (5 × 1011 vg/kg) alone or combined with 100 μg of ImmTOR, either as an admix or administered sequentially. Hepatic vector DNA and SEAP mRNA and serum SEAP levels in the group receiving AAV8-SEAP admixed to ImmTOR versus the other two groups were statistically different at every time point (P < 0.01, except for the 3-day and 7-day time points for vector DNA at P < 0.05, multiple t test), as were anti-AAV IgG levels in groups treated with AAV8-SEAP combined with ImmTOR versus the group receiving AAV8-SEAP alone (P < 0.01, multiple t test).](https://figures.cochat.ai/paper-figures/fa3cf8cbbc2b4177a57ea0c351978a8d/enhancement-of-liver-directed-transgene-expression-at-initial-and-repeat-doses-figure-2.jpg)





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a promising model of coadministration of encapsulated rapamycin (ImmTOR) along with AAV vectors results in decreased capsid-specific humoral response, T cell response, and immune cell infiltration into the target organs, with stable transduction and transgene expression.67”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [67]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: mTORC1-Induced HK1-Dependent Glycolysis Regulates NLRP3 Inflammasome Activation
Moon, J.-S., Hisata, S., Park, M.-A., DeNicola, G. M., Ryter, S. W., Nakahira, K., & Choi, A. M. K. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.05.046 · Cited by 374
RetractedAnalysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881 · cited 3×
“(6) recently highlighted immunogenicity and vector potency as two key challenges in the ability to achieve and maintain therapeutic levels of transgene expression.”
BackgroundInfluential
Cited by
AAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
“217 The ef fi cacy of co-administration of ImmTOR with AAV vectors to control anti-AAV immune responses in patients, as well as potential side effects, will be crucial points for future use in the clinical setting.”
BackgroundrAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
Shen, W., Liu, S., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001263 · Cited by 173
“Other methods include plasmapheresis (57, 58), saline flushing (59), IgG proteases (60), capsid engineering (61–63), and lipid nanoparticle encapsulated rapamycin (64), most of which are under preclinical development.”
BackgroundCAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications
Arjomandnejad, M., Kopec, A. L., & Keeler, A. M. (2022) · Biomedicines · doi:10.3390/biomedicines10020287 · Cited by 171
Sands, E., Kivitz, A., DeHaan, W., Leung, S. S., Johnston, L., & Kishimoto, T. K. (2022) · Nature Communications · doi:10.1038/s41467-021-27945-7 · Cited by 61
Self-citationHemophilia A gene therapy: current and next-generation approaches
Pipe, S. W., Gonen-Yaacovi, G., & Segurado, O. G. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2002842 · Cited by 57
“…recently developed to induce immune tolerance and thereby enhance transgene expression after the first dose of an AAV vector and inhibit adaptive antibody and T cell immune responses against the AAV capsid, allowing for repeated administration of AAV vectors in mice and nonhuman primates [120,121].”
Modern therapeutic approaches to liver-related disorders
Gardin, A., Remih, K., Gonzales, E. M., Andersson, E. R., & Strnad, P. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.015 · Cited by 51
The curious case of AAV immunology
Keeler, A. M., Zhan, W., Ram, S., Fitzgerald, K. A., & Gao, G. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.037 · Cited by 52
Arjomandnejad, M., Sylvia, K., Blackwood, M., Nixon, T., Tang, Q., Muhuri, M., Gruntman, A. M., Gao, G., Flotte, T. R., & Keeler, A. M. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.10.010 · Cited by 44
“Further, a promising model of coadministration of encapsulated rapamycin (ImmTOR) along with AAV vectors results in decreased capsid-specific humoral response, T cell response, and immune cell infiltration into the target organs, with stable transduction and transgene expression.(67) The immunomodulatory effect of Imm…”
BackgroundSłyk, Ż., Stachowiak, N., & Małecki, M. (2024) · Biomedicines · doi:10.3390/biomedicines12071523 · Cited by 44
Ilyinskii, P. O., Michaud, A. M., Rizzo, G. L., Roy, C. J., Leung, S. S., Elkins, S. L., Capela, T., Chowdhury, A., Li, L., Chandler, R. J., et al. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.06.015 · Cited by 39
Self-citationKishimoto, T., Fournier, M., Michaud, A. M., Rizzo, G. L., Roy, C. J., Capela, T., Nukolova, N. V., Li, N., Doyle, L., Fu, F.-N., et al. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2023.103125 · Cited by 40
Self-citationXiang, Z., Kuranda, K., Quinn, W. J., Chekaoui, A., Ambrose, R., Hasanpourghadi, M., Novikov, M., Newman, D., Cole, C., Zhou, X., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.258 · Cited by 37
Enhancement of the Tolerogenic Phenotype in the Liver by ImmTOR Nanoparticles
Ilyinskii, P. O., Roy, C. J., LePrevost, J., Rizzo, G. L., & Kishimoto, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.637469 · Cited by 30
“1 mV (55) with rapamycin load within 8-25% weight and release rate up to 60% at 1 hour or 25-80% at 24 hours.”
BackgroundSelf-citationB cell focused transient immune suppression protocol for efficient AAV readministration to the liver
Rana, J., Herzog, R. W., Muñoz-Melero, M., Yamada, K., Kumar, S. R. P., Lam, A. K., Markusic, D. M., Duan, D., Terhorst, C., Byrne, B. J., et al. (2024) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2024.101216 · Cited by 26
The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy
Puzzo, F., & Kay, M. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.041 · Cited by 31
“107 Furthermore, ImmTOR enabled a second vector administration following an initial treat-ment with AAVs.”
Gene therapies for mucopolysaccharidoses
Rossi, A., & Brunetti‐Pierri, N. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12626 · Cited by 25
“…of AAV vectors with different capsids, 43 co-delivery of AAV with immunomodulatory molecules preventing the formation of neutralizing anti-capsid antibodies, 44 plasmapheresis to remove neutralizing anti-capsid antibodies, 45 or pre-treatment with endopeptidase that can degrade circulating IgG.”
BackgroundBaatartsogt, N., Kashiwakura, Y., Hiramoto, T., Hayakawa, M., Kamoshita, N., & Ohmori, T. (2023) · The Journal of Gene Medicine · doi:10.1002/jgm.3505 · Cited by 23
“use of several immunomodulators has been successful in murine and monkey livers.(24,25) A recent study examined the efficacy of removing pre-existing NAbs by degrading circulating immunoglobulin G (IgG)”
BackgroundGardin, A., & Ronzitti, G. (2023) · Archives de Pédiatrie · doi:10.1016/s0929-693x(23)00227-0 · Cited by 25
Weber, N. D., Odriozola, L., Ros‐Gañán, I., García-Porrero, G., Salas, D., Argemí, J., Combal, J. P., Kishimoto, T., & González‐Aseguinolaza, G. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100713 · Cited by 27
Self-citationIlyinskii, P. O., Roy, C. J., Michaud, A. M., Rizzo, G. L., Capela, T., Leung, S. S., & Kishimoto, T. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad394 · Cited by 22
“Recently, we have described the use of ImmTOR nanoparticles, which encapsulate rapamycin, to induce a tolerogenic response to coadministered vectors that enable successful vector redosing (7, 16, 17, 24).”
BackgroundMethodResultInfluentialSelf-citationEgorova, T. V., Starikova, A. V., & Polikarpova, A. V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111492 · Cited by 20
“Currently approved drugs necessitate doses of 5 × 10 11 –1.33 × 10 14 vg/kg for systemic injections [112].”
InfluentialYadav, M., Yoo, K. W., Atala, A., & Lu, B. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.09.009 · Cited by 19
“Co-delivering ImmTOR (a lipid nanoparticle with rapamycin) and an AAV vector inhibited immune responses to the vector and allowed repeated delivery.(52) Thus, co-delivery of ImmTOR and CLCN5 LV vectors might inhibit transgene-induced immune response and elongate the duration of therapeutic effects.”
BackgroundHemophilia as a blueprint for gene therapy
Ragni, M. V. (2021) · Science · doi:10.1126/science.abg0856 · Cited by 16
Hahn, P. A., & Martins, M. A. (2023) · Journal of Virus Eradication · doi:10.1016/j.jve.2023.100316 · Cited by 15
In vivo Gene Therapy to the Liver and Nervous System: Promises and Challenges
Cantore, A., Fraldi, A., Meneghini, V., & Gritti, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.774618 · Cited by 17
Choi, S. J., Yi, J. S., Lim, J., Tedder, T. F., Koeberl, D. D., Jeck, W. R., Desai, A. K., Rosenberg, A. S., Sun, B., & Kishnani, P. S. (2023) · The Journal of Gene Medicine · doi:10.1002/jgm.3509 · Cited by 14
Muñoz-Melero, M., & Biswas, M. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.227 · Cited by 14
Emerging approaches to induce immune tolerance to therapeutic proteins
Noel, J. C., Lagassé, D., Golding, B., & Sauna, Z. E. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.10.002 · Cited by 13
Treatment of metabolic disorders using genomic technologies: Lessons from methylmalonic acidemia
Venturoni, L. E., & Venditti, C. P. (2022) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12534 · Cited by 12
“Selecta Biosciences has developed a tolerogenic nanoparticle that encapsulates rapamycin known as ImmTOR (Figure 2A),79–82 which causes long-term suppression of humoral and T cell responses when coadministered with an AAV therapy.(80,96) When combining ImmTOR with an MMUT rAAV in the Mmut / ; Tg MCK Mmut mouse model,…”
BackgroundShi, X., Bortolussi, G., Collaud, F., Brun, P.-R. L., ten Bloemendaal, L., Guerchet, N., de Waart, D. R., Sellier, P., Duijst, S., Veron, P., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101363 · Cited by 10
“22,31,34,35 We have investigated the potential use of ImmTOR tolerogenic nanoparticles in two relevant animal models of CNS, Gunn rats ( Ugt1a (cid:1) / (cid:1) ) and Ugt1a (cid:1) / (cid:1) mice.”
Self-citationSynergism of dual AAV gene therapy and rapamycin rescues GSDIII phenotype in muscle and liver
Jauze, L., Vie, M., Miagoux, Q., Rossiaud, L., Vidal, P., Montalvo-Romeral, V., Saliba, H., Jarrige, M., Polvèche, H., Nozi, J., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.172614 · Cited by 11
“Differently from what previously reported (36–38), rapamycin treatment in liver did not result in increased transduction, and it seems to induce some degree of toxicity.”
ResultGan, C., Leng, M., Liu, Y., Zheng, Z., He, S., Qiao, W., Lin, X., Xiao, Y., Ye, J., Zhou, L., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101399 · Cited by 7
Tsaregorodtseva, T. S., Radyukhina, M. A., Ayupova, A. I., Solovyeva, V. V., Sufianov, A. A., Суфианова, Г. З., & Rizvanov, A. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114818 · Cited by 5
“Intracellular release of rapamycin mediates a complex immunomodulatory effect, including suppression of humoral and T-cell immune responses [195], enhancement of regulatory Treg differentiation [196], and reduction of pro-inflammatory cytokine IL-1 β production [197].”
Skeletal-muscle-targeted non-viral delivery of full-length DMD mRNA for Duchenne muscular dystrophy
Tian, Y. W., Liu, Y., Tong, Y., Huntoon, K. M., Yang, L., Shi, J., Ma, Y., Dong, S., Jeong, S. D., Estania, A. P., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01689-5 · Cited by 6
Perez-Iturralde, A., Carte, B., & Aldabe, R. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.171 · Cited by 5
“Interestingly, mTOR inhibition using rapamycin, naked or administered inside nanoparticles, 9 has been shown to increase AAV-encoded transgene expression in mouse and nonhuman primate livers after vector administration.”
Lipid-Rapamycin Nanovaccines Overcome the Antidrug Antibody Barrier in Biologic Therapies
Li, X., Ma, M., An, N. A., Yao, X., Yasen, G., Zhong, M., Jin, Z., He, Z., Wang, Y., & Liu, H. (2025) · ACS Nano · doi:10.1021/acsnano.4c11928 · Cited by 5
ZNF146 accelerates lung adenocarcinoma progression through MDM2/p53 and PHGDH/ferroptosis
Zhu, J., Ren, S., Yi, Y., Wu, Z., Lin, H., Shan, G., Huang, X., Pan, B., Hu, Z., Sui, Q., et al. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01433-7 · Cited by 3
Ramadan, A. M., Rao, P., Allababidi, S., Khashan, R., & Fathallah, A. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083830 · Cited by 3
“PS-mediated tolerance usually results in a reduction, but not elimination, of the immune response [15].”
Yu, K., Sun, C., Dong, M., Song, S., Wang, Y., Zhao, N., Xu, N., & Liu, W. (2025) · Toxicon · doi:10.1016/j.toxicon.2025.108289 · Cited by 2
Burns, A., & Datta, S. (2025) · Biotechnology Journal · doi:10.1002/biot.70157 · Cited by 2
ImmTORTM to amplify the efficacy and reduce immunogenicity of biologics
Brunn, C., & Kishimoto, T. (2021) · Emerging Topics in Life Sciences · doi:10.1042/etls20210127 · Cited by 2
Self-citationLou, Y., Yang, P., Wang, Y., Liu, X., Guo, Z., Geng, Z., Lin, J., Wang, J., Zhang, M., Guo, X., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123144 · Cited by 1
In Vivo Selection of S/MAR Sequences to Favour AAV Episomal Maintenance in Dividing Cells
Llanos-Ardaiz, A., Lantero, A., Neri, L., Mauleón, I., de Galarreta, M. R., Trigueros‐Motos, L., Weber, N. D., Ferrer, V., Aldabe, R., & González‐Aseguinolaza, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312734 · Cited by 1
“Research has also been dedicated to using different capsid serotypes for subsequent administrations [10–12] and to inducing immunological tolerance to AAVs with the initial treatments [13–15].”
Ou, Y., Wu, F., He, C., Luo, S., Guo, Z., Zhang, Y., Hu, R., Xu, Y., Tang, X., Zhao, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71194-5 · Cited by 1
Yu, K., Geng, X. L., Sun, C., Zhang, Y., Song, S., Wang, Y., Huo, M., Lu, N., Dong, M., Yu, L., et al. (2026) · Giant · doi:10.1016/j.giant.2026.100396 · Cited by 1
Burns, A., Ramos‐Sono, D., & Datta, S. (2025) · Biotechnology Progress · doi:10.1002/btpr.70017 · Cited by 1
“27,28 Empty AAV capsids show a dark circle in the middle of the capsid due to the accumulation of uranyl acetate at the center of the capsid during TEM sample preparation, while full AAV capsids do not have this dark spot.”
Singh, P. Y., & Luo, X. (2021) · Transplantation · doi:10.1097/tp.0000000000003760
Optimizing gene therapy for infant mice with citrullinemia type 1
Bazo, A. (2023) · Depósito Académico Digital Universidad de Navarra (University of Navarra) · doi:10.15581/10171/67875
Vicidomini, A. (2024) · Open Research Online (The Open University) · doi:10.21954/ou.ro.00097257
Hardet, R., Wang, S.-H., Delignat, S., Blandin, M., Digigow, R. G., Gottwick, C., Heine, M., Mesquita, L., Fanzutti, M., Vocaturo, A.-L., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.009
“50,51 In fact, LSECs may appear even superior to classical APCs, as they have been reported to exhibit 10-fold higher antigen-uptake capabilities and 2-fold higher cross-presentation efficiency in comparison to dendritic cells.”
AAV vectors for cancer gene therapy
Lee, M., Park, J., Park, J. H., & Curiel, D. T. (2026) · Advances in cancer research · doi:10.1016/bs.acr.2026.02.005
Gardin, A. (2023) · theses.fr (ABES) · doi:10.70675/ac839ccez52b2z45bez9294ze72731823d9b · Cited by 1
Bellia, F., Ruggieri, A. G., Amodei, L., Potenza, F., Dufrusine, B., Panella, V., Pizzo, F., Lamolinara, A., Iezzi, M., Federici, L., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118014 · Cited by 1
Vicidomini, A., Boisgérault, F., Romano, G., Guarnaccia, C., Vidal, P., Collaud, F., Soria, L. R., Sabbata, G. D., Tedesco, N., Lisjak, M., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201793
Self-citationLi, K., Qi, H., 信瑶瑶, Qin, L., Cheng, Y., & Yao, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1930837
“…vaccine particles (SVP-Rapamycin/ImmTOR), co-administered with vector, induce antigen-specific tolerance to the capsid, suppress anti-AAV IgG, and have enabled successful vector re-administration in mice and non-human primates (Meliani et al., 2018; Kishimoto, 2020; Ilyinskii et al., 2021).”
Lyu, P., Bostancı, A., Jiang, C., Yoo, K. W., Broadhurst, R., Atala, A., & Lu, B. (2026) · Gene Therapy · doi:10.1038/s41434-026-00655-9
Future directions and challenges of drug development and non-human primate models
Wang, Z., & Wu, X. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124768
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Metadata
- Authors
- Ilyinskii, P. O., Michaud, A. M., Roy, C. J., Rizzo, G. L., Elkins, S. L., Capela, T., Chowdhury, A. C., Leung, S. S., & Kishimoto, T. K.
- Affiliations
- Selecta Biosciences (United States) (US)
- Corresponding author
- Kishimoto, Takashi K.
- ORCID
- Venue
- Science Advances
- Published
- 2021-02-26
- Volume
- 7
- Issue
- 9
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC7904260
- OpenAlex
- W3129500930
- Cited by
- 56
- References
- 40
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 9 · 2023: 12 · 2022: 9 · 2021: 8
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- adeno-associated virus vectors, rapamycin, liver-directed gene delivery, repeated dosing, adaptive immunity, inborn errors of metabolism, systemic gene therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.